CLL combos coming, melanoma semblances only skin deep

As researchers and clinicians converge on New Orleans for the annual meeting of the American Society of Hematology (ASH) this weekend, one thing is clear: There will be a bumper crop of data on drugs for the treatment of chronic lymphocytic leukemia (CLL). The society itself is putting on a press briefing on “the changing landscape of CLL.”